Annual report 2023

Group structure and shareholders

medmix Ltd is subject to the laws of Switzerland, in particular Swiss corporate and stock exchange laws. The company also applies the Swiss Code of Best Practice for Corporate Governance. medmix Ltd has a single share class and has separated the functions of Chairman of the Board of Directors and CEO. The information in the following section is set out in the order defined by the SIX Exchange Regulation AG Directive on Information Relating to Corporate Governance (RLCG), with subsections summarized as far as possible. medmix Ltd.’s consolidated financial statements are prepared in accordance with IFRS Accounting Standards, and, in certain sections, readers are referred to the financial reporting section in this annual report 2023. medmix Ltd reports the compensation of the Board of Directors and the Executive Committee in the compensation report. Unless otherwise indicated, the following information refers to the situation on December 31, 2023. Further information on corporate governance is published on  

Group structure

The group is organized into two business areas, Healthcare and Consumer & Industrial, and the operational group structure corresponds to these reported business areas. More information on the group structure can be found under note 3 to the consolidated financial statements in the financial reporting section. medmix Ltd is the only legal entity belonging to the medmix group which is listed on a stock exchange. medmix Ltd has its registered office in Baar, Switzerland. Its shares are listed and traded on the SIX Swiss Exchange in Zurich (ISIN CH1129677105). On December 31, 2023, the market capitalization of all issued shares of medmix Ltd was CHF 783'985'030.00. Information on the subsidiaries included in the consolidation can be found under note 33 to the consolidated financial statements. The list comprises all majority-owned consolidated direct and indirect subsidiaries of medmix Ltd.

Significant shareholders

According to notifications in accordance with the Swiss Financial Market Infrastructure Act received from shareholders of medmix Ltd, the following shareholders held more than 3% of medmix Ltd’s registered share capital: As published on the SIX disclosure platform on October 8, 2021, Viktor F. Vekselberg held 40.54% of medmix Ltd's shares. The shares are directly held by Tiwel Holding AG. Further, The Capital Group Companies, Inc. held 3.03% of medmix Ltd's shares as published on the SIX disclosure platform on August 24, 2023, while FIL Limited held 4.90%, as published on November 17, 2021. As published on October 8, 2021, UBS Fund Management (Switzerland) AG held 4.35% of medmix Ltd's shares. For information on shareholders of medmix Ltd that have reported shareholdings of over 3% or a reduction of shareholdings below 3%, please refer to the website of the Disclosure Office of SIX Swiss Exchange ( For the positions held by medmix Ltd and information on shareholders, see note 21 to the consolidated financial statements.


There are no cross-shareholdings where the capital or voting stakes on either side exceed the threshold of 5%.